Thai Airways shares jump 231% as trading resumes after 5-year halt
The national carrier entered bankruptcy-protected restructuring in 2020 at the onset of the pandemic.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Data Science
MCA
Management
others
PGDM
Public Policy
Degree
healthcare
Project Management
Data Science
Digital Marketing
Product Management
Others
Healthcare
Design Thinking
Technology
MBA
Operations Management
Data Analytics
Artificial Intelligence
Cybersecurity
Leadership
Finance
CXO
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK DABS India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
E&ICT Academy, Indian Institute of Technology Guwahati
CERT-IITG Prof Cert in DS & BA with GenAI India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
E&ICT Academy, Indian Institute of Technology Guwahati
CERT-IITG Postgraduate Cert in AI and ML India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
30 Weeks
IIM Kozhikode
SEPO - IIMK-AI for Senior Executives India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIT Madras
CERT-IITM Advanced Cert Prog in AI and ML India
Starts on
undefined
Get Details
ETMarkets WhatsApp channel
)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
Apple To Invest Additional $100 Billion In US: White House Official
Apple will invest an additional $100 billion in the United States, taking its total pledge to $600 billion over the next four years, a senior White House official said Wednesday. The announcement, which was first reported by US media, will be officially made later Wednesday at 4:30 pm (2030 GMT) at a White House event with President Donald Trump. In February, Apple said it would spend more than $500 billion in the United States and hire 20,000 people, with Trump quickly taking credit for the decision. The Silicon Valley-based giant said it was its "largest-ever spend commitment," which came as tech companies battle for dominance in developing artificial intelligence technology. It builds on plans announced in 2021, when the company founded by Steve Jobs said that it would invest $430 billion in the US and add 20,000 jobs over the next five years. Trump, who has pushed US companies to shift manufacturing home by slapping tariffs on trading partners, claimed that his administration was to thank for the investment. Apple reported a quarterly profit of $23.4 billion in late July, topping forecasts despite facing higher costs due to Trump's sweeping levies. Tariffs are essentially a tax paid by companies importing goods to the United States. This means Apple is on the hook for tariffs on iPhones and other products or components it brings into the country from abroad.
Deccan Herald
2 hours ago
- Deccan Herald
European shares rise as investors buy dips, shrug off US threats
European shares extended gains on Wednesday as investors bought into recent market weakness, brushing aside fresh U.S. tariff threats and digesting a mixed batch of corporate earnings. The pan-European STOXX 600 index was up 0.3%, as of 0713 GMT, rising for a third consecutive session after touching a five-week low on Friday. Germany's blue-chip DAX and France's CAC 40 climbed 0.5% and 0.4%, respectively. Shares of Commerzbank rose nearly 1% after the German lender posted its quarterly net profit above expectations and raised parts of its full-year outlook. Siemens Energy said it expects to hit the upper end of its 2025 growth outlook estimates. Shares rose 1.2%. Swiss President Karin Keller-Sutter was set to meet U.S. Secretary of State Marco Rubio as Switzerland seeks to negotiate the 39% tariff scheduled to take effect on Thursday. Switzerland's benchmark SMI index edged 0.1% lower. European healthcare stocks slipped 0.7%, weighed down by a 1.3% drop in heavyweight Novo Nordisk after the Danish drugmaker maintained its full-year outlook, just days after slashing its 2025 sales outlook. The Wegovy maker said it would cut costs after losing nearly $95 billion in market value last week.
Economic Times
2 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
